Carboxylic acid drug-induced DNA nicking in HEK293 cells expressing human UDP-glucuronosyltransferases: Role of acyl glucuronide metabolites and glycation pathways

Chemical Research in Toxicology

Volumn 20, Issue 10, 2007, Pages 1520-1527

  Southwood, Hamish T ^a,b   DeGraaf, Yvette C ^a,b   Mackenzie, Peter I ^c   Miners, John O ^c   Burcham, Philip C ^d   Sallustio, Benedetta C ^a,b  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c FLINDERS UNIVERSITY   (Australia)

^d UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGUANIDINE; BENOXAPROFEN; BEZAFIBRATE; BORNEOL; CARBOXYLIC ACID DERIVATIVE; CLOFIBRIC ACID; DEFEROXAMINE; DNA; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A9; GLUCURONOSYLTRANSFERASE 2B7; PROBENECID; SODIUM HYDROXIDE;

ARTICLE; CELL STRAIN HEK293; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; GENOTOXICITY; GLYCATION; HUMAN; HUMAN CELL; INCUBATION TIME; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTICHOLESTEREMIC AGENTS; CELL LINE; CELL SURVIVAL; CLOFIBRIC ACID; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; GLYCOSYLATION; GUANIDINES; HUMANS; KIDNEY; TRANSFECTION;

EID: 35848959492     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx700188x     Document Type: Article

References (47)

1. Sallustio, B. C., Sabordo, L., Evans, A. M., and Nation, R. L. (2000) Hepatic disposition of electrophilic acyl glucuronide conjugates. Curr. Drug Metab. 1, 163-180.
2. Bailey, M. J., and Dickinson, R. G. (2003) Acyl glucuronide reactivity in perspective: biological consequences. Chem.-Biol. Interact. 145, 117-137.
3. Spahn-Langguth, H., and Benet, L. Z. (1992) Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism. Drug Metab. Rev. 24, 5-48.
4. 13C labelling and nuclear magnetic resonance spectroscopy. Drug Metab. Dispos. 26, 457-464.
5. Qui, Y., Burlingame, A. L., and Benet, L. Z. (1998) Mechanisms for covalent binding of benoxaprofen glucuronide to human serum albumin. Drug Metab. Dispos. 26, 246-256.
6. Smith, P. C., and Wang, C. ( 1992) Nonenzymic glycation of albumin by acyl glucuronides in vitro: comparisons of reactions with reducing sugars. Biochem. Pharmacol. 44, 1661-1668.
7. Lee, A. T., and Cerami, A. (1990) In vitro and in vivo reactions of nucleic acids with reducing sugars. Mutat. Res. 238, 185-191.
8. Stopper, H., Schinzel, R., Sebekova, K., and Heidland, A. (2003) Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 190, 151-156.
9. Wolff, S. P., and Dean, R. T. (1987) Glucose autoxidation and protein modification. The potential role of "autoxidative glycosylation" in diabetes. Biochem. J. 245, 243-250.
10. Sallustio, B. C., DeGraaf, Y. C., Weekley, J. S., and Burcham, P. C. (2006) Bioactivation of carboxylic acid compounds by UDP- glucuronosyltransferases to DNA-damaging intermediates: role of glycoxidation and oxidative stress in genotoxicity. Chem. Res. Toxicol. 19, 683-691.
11. Cayen, M. N. (1985) Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol. Ther. 29, 157-204.
12. Sallustio, B. C., Harkin, L. A., Mann, M. C., Krivickas, S. J., and Burcham, P. C. (1997) Genotoxicity of acyl glucuronide metabolites formed from clofibric acid and gemfibrozil: a novel role for phase-II-mediated bioactivation in the hepatocarcionogenicity of the parent aglycones. Toxicol. Appl. Pharmacol. 147, 459-464.
13. Ghaoui, R., Sallustio, B. C., Burcham, P. C., and Fontaine, F. R. (2003) UDP-glucuronosyltransferase-dependent biqactivation of clofibric acid to a DNA-damaging intermediate in mouse hepatocytes. Chem.-Biol. Interact. 145, 201-211.
14. Radominska-Randya, A., Pokrovskaya, I. D., Xu, J., Little, J. M., Jude, A. R., Kurten, R. C., and Czemik, P. J. (2001) Nuclear UDP- glucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. Arch. Biochem. Biophys. 399, 37-48.
15. Jin, C., Miners, J. O., Lillywhite, K. J., and Mackenzie, P. I. (1993) Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs. J Pharmacol. Exp. Ther. 264, 475-479.
16. Green, M. D., King, C. D., Mojarrabi, B., Mackenzie, P. I., and Tephly, T. R. (1998) Glucuronidation of amines and other xenobiotics catalysed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab. Dispos. 26, 507-512.
17. Ebner, T., and Burchell, B. (1993) Substrate specificities of two stably expressed human liver UDP-glucuronosyltransferases of the UGT1 gene family. Drug Metab. Dispos. 21, 50-55.
18. Sakaguchi, K., Green, M., Stock, N., Reger, T. S., Zunic, J., and King, G (2004) Glucuronidation of carboxylic acid containing compounds by UDP-glucuronosyltransferase isoforms. Arch. Biochem. Biophys. 424, 219-225.
19. Uchaipichat, V., Mackenzie, P. I., Guo, X.-H., Gardenr-Stephen, D., Galetin, A., Houston, J. B., and Miners, J. O. (2004) Human UDP- glucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos. 32, 413-423.
20. Park, J. G., Kramer, B. S., Steinberg, S. M., Carmichael, J., Collins, J. M., Minna, J. D., and Gazdar, A. F. (1987) Chemosensitivity testing of human colorectal carcinoma cell lines using a tetrazolium-based colorimetric assay. Cancer Res. 47, 5875-5879.
21. Hanioka, N., Jinno, H., Tanaka-Kagawa, T., Nishimura, T., and Ando, M. (2001) Determination of UDP-glucuronosyltransferase UGT1A6 activity in human and rat liver microsomes by HPLC with UV detection. J. Pharm. Biomed. Anal. 25, 65-75.
22. Bailey, M. J., and Dickinson, R. G. (1996) Chemical and immunochemical comparison of protein adduct formation of four carboxylate drugs in rat liver and plasma. Chem. Res. Toxicol. 9, 659-666.
23. Singh, N. P., McCoy, M., Tice, R. R., and Schneider, E. (1988) A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175, 184-191.
24. Tice, R. R., Agurell, E., Anderson, D., Burinson, B., Hartman, A., Kobayashi, H., Miyamae, Y., Rojas, E., Ryu, J. C., and Sasaki, Y. F. (2000) Single-cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35, 206-221.
25. Burcham, P. C., and Fontaine, F. R. (2001) Extensive protein carbonylation precedes acrolein-mediated cell death in mouse haptocytes. J. Biochem. Mol.Toxicol. 15, 309-316.
26. Barbier, O., Levesque, E., Belanger, A., and Hum, D. W. (1999) UGT2B23, a novel uridine diphosphate glucuronosyltransferase enzyme expressed in steroid target tissues that conjugate androgen and estrogen metabolites. Endocrinology 140, 5538-5548.
27. Barbier, O., Belanger, A., and Hum, D. W. (1999) Cloning and characterization of a simian UDP-glucuronosyltransferase enzyme UGT2B20, a novel C19 steroid-conjugating protein. Biochem. J. 337, 567-574.
28. Miners, J. O., Lillywhite, K. J., Matthews, A. P., Jones, M. E., and Birkett, D. J. (1988) Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem. Pharmacol. 37, 665-671.
29. Faed, E. M., and McQueen, E. G. (1979) Measurement of clofibric acid (CPIB) metabolites in plasma of patients on Clofibrate therapy. Clin. Exp. Pharmacol. Physiol. 6, 267-273.
30. Oliver, M. F., Heady, J. A., Morris, J. N., and Cooper, J. (1978) A co-operative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br. Heart J. 40, 1069-1118.
31. Oliver, M. F., Heady, J. A., Morris, J. N., and Cooper, J. (1980) W.H.O. cooperative trial on primary prevention of ischaemic heart disease using Clofibrate to lower serum cholesterol: mortality follow-up. Lancet August 23, 379-385.
32. Abshagen, U., Bablok, W., Koch, K., Lang, P. D., Schmidt, H. A. E., Senn, M., and Stork, H. (1979) Disposition pharmacokinetics of bezafibrate in man. Eur. J. Clin. Pharmacol. 16, 31-38.
33. Cunningham, R. F., Israili, Z. H., and Dayton, P. G. (1981) Clinical pharmacokinetics of probenecid. Clin. Pharmacokinet. 6, 135-151.
34. Hansen-Moller, J., and Schmit, U. (1991) Rapid high-performance liquid chromatographic assay for the simultaneous determination of probenecid and its glucuronide in urine. Irreversible binding of probenecid to serum albumin. J. Pharm. Biomed. Anal. 9, 65-73.
35. Hirano, M., Maeda, K., Shitara, Y., and Sugiyama, Y. (2004) Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311, 139-146.
36. Hagmann, W., Nies, A., Konig, J., Frey, M., Zentgraf, H., and Keppler, D. (1999) Purification of the human apical conjugate export pump MRP2. Reconstitution and functional characterization as substrate-stimulated ATPase. Eur. J. Biochem. 265, 281-289.
37. Zeng, H., Liu, G., Rea, P. A., and Kruh, G. D. (2000) Transport of amphipathic anions by human multidrug resistance protien 3. Cancer Res. 60, 4779-4784.
38. Henderson, L., Wolfreys, A., Fedyk, J., Bourner, C., and Windebank, S. (1998) The ability of the comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis 13, 89-94.
39. Ding, A., Zia-Amirhosseini, P., McDonagh, A. F., Burlingame, A. L., and Benet, L. Z. (1995) Reactivity of tolmetin glucuronide with human serum albumin. Identification of binding sites and mechanisms of reaction by tandem mass spectrometry. Drug Metab. Dispos. 23, 369-376.
40. Baynes, J. W. (2002) The Maillard hypothesis on aging: time to focus on DNA. Ann. N.Y. Acad. Sci. 959, 360-367.
41. Khalifah, R. G., Baynes, J. W., and Hudson, B. G. (1999) Amadorins: novel post-amadori inhibitors of advanced glycation reactions. Biochem. Biophys. Res. Commun. 257, 251-258.
42. Lee, A.T., and Cerami, A. (1987) The formation of reactive intermediate(s) of glucose 6-phosphate and lysine capable of rapidly reacting with DNA. Mutat Res. 179, 151-158.
43. Ashby, J., Brady, A., Elcombe, C. R., Elliot, B. M., Ishamael, J., Odum, J., Tugwood, J. D., Kettle, S., and Purchase, I. F. H. (1994) Mechanistically-based human hazard assessment of peroxisome proliferator-induced hepatocarcinogenesis. Human Exp. Toxicol. 13, S1-S117.
44. Reisenbichler, H., and Eckl, P. (1993) Genotoxic effects of selected peroxisome proliferators. Mutat. Res. 286, 135-144.
45. Guengerich, F. P., Gillam, E. M. J., and Shimada, T. (1996) New applications of bacterial systems to problems in toxicology. Crit. Rev. Toxicol. 26, 551-583.
46. Kamataki, T., Suzuki, A., Kushida, H., Iwata, H., Watanabe, M., Nohmi, T., and Fujita, K. (1999) Establishment of a Salmonella tester strain highly sensitive to mutagenic heterocyclic amines. Cancer Lett. 143, 113-116.
47. Fujita, K., Mogami, A., Hayashi, A., and Kamataki, T. (2000) Establishment of a Salmonella strain expressing catalytically active human UDP-glucuronosyltransferase 1A1 (UGT1A1). Life Sci. 66, 1955-1967.